相似文献
1
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Antimicrob Agents Chemother. 2015 Oct 19;60(1):621-3. doi: 10.1128/AAC.01211-15. Print 2016 Jan.
2
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
J Biol Chem. 2015 Aug 21;290(34):20984-20994. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.
3
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Antimicrob Agents Chemother. 2015 Sep;59(9):5220-5. doi: 10.1128/AAC.00786-15. Epub 2015 Jun 15.
4
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
Int J Antimicrob Agents. 2016 Sep;48(3):328-30. doi: 10.1016/j.ijantimicag.2016.05.018. Epub 2016 Jul 12.
5
Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Clinical Isolates in Nanjing, China, 2014 to 2018.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.00863-20.
6
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Antimicrob Agents Chemother. 2014 Sep;58(9):5585-8. doi: 10.1128/AAC.03090-14. Epub 2014 Jun 30.
7
High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of Neisseria gonorrhoeae isolates in Cuba, 1995-1998.
Sex Transm Dis. 2003 May;30(5):443-8. doi: 10.1097/00007435-200305000-00012.
8
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone.
BMC Infect Dis. 2014 Nov 27;14:622. doi: 10.1186/s12879-014-0622-0.
9
Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009.
Antimicrob Agents Chemother. 2011 Aug;55(8):3882-8. doi: 10.1128/AAC.00155-11. Epub 2011 May 23.
10
Efficacy of Gentamicin Alone and in Combination with Ceftriaxone, Ertapenem, and Azithromycin against Multidrug-Resistant Neisseria gonorrhoeae.
Microbiol Spectr. 2021 Oct 31;9(2):e0018121. doi: 10.1128/Spectrum.00181-21. Epub 2021 Oct 20.
引用本文的文献
1
Tetracycline-resistant global estimates-impacts on doxycycline post-exposure prophylaxis implementation and monitoring: a systematic review.
JAC Antimicrob Resist. 2025 Jul 9;7(4):dlaf120. doi: 10.1093/jacamr/dlaf120. eCollection 2025 Aug.
2
Late-stage functionalization of 5-nitrofurans derivatives and their antibacterial activities.
RSC Adv. 2023 Jan 20;13(5):3204-3209. doi: 10.1039/d2ra07676d. eCollection 2023 Jan 18.
3
Molecular Regulatory Mechanisms Drive Emergent Pathogenetic Properties of .
Microorganisms. 2022 Apr 28;10(5):922. doi: 10.3390/microorganisms10050922.
4
Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Clinical Isolates in Nanjing, China, 2014 to 2018.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.00863-20.
5
Azithromycin resistant gonococci: a literature review.
Antimicrob Resist Infect Control. 2020 Aug 18;9(1):138. doi: 10.1186/s13756-020-00805-7.
6
Global Network Analysis of Neisseria gonorrhoeae Identifies Coordination between Pathways, Processes, and Regulators Expressed during Human Infection.
mSystems. 2020 Feb 4;5(1):e00729-19. doi: 10.1128/mSystems.00729-19.
7
High susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical isolates from Thailand (2018) and South Africa (2015-2017).
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01479-19. Epub 2019 Sep 23.
8
Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin.
J Clin Microbiol. 2019 Aug 26;57(9). doi: 10.1128/JCM.00567-19. Print 2019 Sep.
9
Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.
PLoS One. 2019 Apr 3;14(4):e0213312. doi: 10.1371/journal.pone.0213312. eCollection 2019.
10
Transcriptome Analysis of Neisseria gonorrhoeae during Natural Infection Reveals Differential Expression of Antibiotic Resistance Determinants between Men and Women.
mSphere. 2018 Jun 27;3(3). doi: 10.1128/mSphereDirect.00312-18. Print 2018 Aug 29.
本文引用的文献
1
In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.
2
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
J Biol Chem. 2015 Aug 21;290(34):20984-20994. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.
3
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Antimicrob Agents Chemother. 2015 Sep;59(9):5220-5. doi: 10.1128/AAC.00786-15. Epub 2015 Jun 15.
4
Twenty-five-year changing pattern of gonococcal antimicrobial susceptibility in Shanghai: surveillance and its impact on treatment guidelines.
BMC Infect Dis. 2014 Dec 30;14:731. doi: 10.1186/s12879-014-0731-9.
5
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22.
6
Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated from Guangzhou, China, 2000 to 2005 and 2008 to 2013.
Sex Transm Dis. 2015 Jan;42(1):27-9. doi: 10.1097/OLQ.0000000000000218.
7
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone.
BMC Infect Dis. 2014 Nov 27;14:622. doi: 10.1186/s12879-014-0622-0.
8
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10.
9
Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014.
Euro Surveill. 2014 Jul 31;19(30):20862. doi: 10.2807/1560-7917.es2014.19.30.20862.
10
Antibiotic susceptibility of Neisseria gonorrhoeae isolates from Guangzhou, China, during 2002-2011.
Jpn J Infect Dis. 2014;67(4):288-91. doi: 10.7883/yoken.67.288.
Zotero 插件